Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Given Average Rating of Buy by Analysts

Shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA – Get Free Report) have received a consensus rating of “Buy” from the ten analysts that are covering the stock, MarketBeat reports. Ten analysts have rated the stock with a buy rating. The average 12 month price objective among analysts that have updated their coverage on the stock in […]

Related Keywords

United States ,Piper Sandler ,Iovance Biotherapeutics ,Avoro Capital Advisors ,Goldman Sachs Group ,Nasdaq ,Barclays ,Iovance Biotherapeutics Inc ,Artisan Partners Limited Partnership ,Vanguard Group Inc ,Wells Fargo Company ,Pricet Rowe Associates Inc ,Get Free Report ,Wells Fargo ,Capital Advisors ,Partners Limited Partnership ,Get Free ,